Corporate History

Founded in Shiba, Minato-ku, Tokyo to contribute to research and development of anti-cancer medicine, cancer therapy and cancer diagnosis based on oncogenes and proteins.

Commenced collaboration with the Institute of Medical Science, University of Tokyo.

Head office moved to Shiroganedai, Minato-ku, Tokyo.

Opened research laboratory at the same place as head office in Minato-ku, Tokyo.

Listed on the Tokyo Securities Exchange Mothers Index.

Head office and head office laboratory facilities moved to Takatsu-ku, Kawasaki city, Kanagawa prefecture, and opened Drug Discovery Laboratory at the same address.

Founded Vaccine Science Inc., consolidated subsidiary company of OTS, to develop peptide vaccines.

Associated company Immunas Pharma, Inc. becomes a consolidated subsidiary of OTS through its stock acquisition.

Merged with consolidated subsidiary company Vaccine Science Inc.

Established Laboratoires OncoTherapy Science France S.A.R.L., a consolidated subsidiary, to contribute in research and development of anti-cancer medicine such as antibody medicine in France.

Established Cancer Precision Medicine, Inc., a consolidated subsidiary which will conduct the genome analysis of cancer, liquid biopsy, and development of new immunotherapy including the neoantigen prediction.

Cancer Precision Medicine, Inc. changed a corporate joint venture with OncoTherapy Science, Inc. and Theragen Etex Co., Ltd..

Company Split Tumor Immunology Dept. from OncoTherapy Science, to Cancer Precision Medicine, Inc.

Opened Clinical Lab. of Cancer Precision Medicine, Inc..